Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

No BS RX vs Semaglutide Online

By GLP-1 ScorecardUpdated

No BS RXFactor scores not reassessed.
Site position #23

Higher score

Semaglutide OnlineFactor scores not reassessed.
Site position #71

Lower score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 74.3/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

Semaglutide Online does not publish a semaglutide price, so its Semaglutide Online review sets out what it does disclose, while the No BS RX review explains the conditions attached to No BS RX's figure. The semaglutide cost page compares published rates across the field. Ask Semaglutide Online for a written total before treating either one as the cheaper choice.

If neither one fits, No BS RX vs Sesame Care and Semaglutide Online vs Sesame Care compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the bmiMD review covers one graded close to these two, at 79.2/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +26
92
66
Dose & formulationSemaglutide Online +6
90
96
Clinical oversightSemaglutide Online +9
72
81
Labs & monitoringNo BS RX +16
68
52
FulfillmentNo BS RX +9
94
85
Contract termsNo BS RX +19
74
55
No BS RX · top barSemaglutide Online · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNo BS RXSemaglutide Online
WeighScore82.8/10074.3/100
GradeB−C
Site position#23#71
Semaglutide$149/mo advertised for standard compounded injection; low-dose priced separatelyConflicting price displays
Tirzepatide$225/mo advertised for standard compounded injection; low-dose priced separately$299/mo (advertised compounded price, selected quote required)
CoverageConfirm program availability for your stateAlabama excluded; confirm eligibility
Brand-name accessYesYes
Oral / sublingualYesYes
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period
Semaglutide Online

Site position #71 · C

Factor scores not reassessed.

Strengths

  • Publishes separate compounded and branded pricing.
  • States that its evaluation guarantee excludes medication charges.

What to consider

  • The homepage gives conflicting semaglutide prices and cancellation descriptions.
  • Confirm the selected term, renewal and refund terms.

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard